** Shares of Solid Biosciences SLDB.O rises 51.9% to $6.12

** Co says its experimental gene therapy for a rare muscle wasting disorder was well-tolerated in 6 participants dosed in an early-stage study

** Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, which interferes with the production of proteins needed to form healthy muscles

** Says no serious adverse events were observed

** Also says that some patients showed significant improvements in multiple muscle health biomarkers

** Separately, co's 35.7 mln stock offering priced at $4.03 each, which was the last closing price of its shares

** SLDB has fallen ~56% in the last 12 months

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))